The Current Status of Anti-GPCR Drugs Against Different Cancers

Overview

Journal J Pharm Anal

Specialty Chemistry

Date 2021 Jan 11

PMID 33425448

Citations 26

Authors

Sana Usman

Maria Khawer

Shazia Rafique

Zara Naz

Komal Saleem

Affiliations

Soon will be listed here.

Abstract

G protein coupled receptors (GPCRs) have emerged as the most potential target for a number of drug discovery programs ranging from control of blood pressure, diabetes, cure for genetic diseases to treatment of cancer. A panel of different ligands including hormones, peptides, ions and small molecules is responsible for activation of these receptors. Molecular genetics has identified key GPCRs, whose mutations or altered expressions are linked with tumorgenicity. In this review, we discussed recent advances regarding the involvement of GPCRs in the development of cancers and approaches to manipulating the mechanism behind GPCRs involved tumor growth and metastasis to treat different types of human cancer. This review provides an insight into the current scenario of GPCR-targeted therapy, progress to date and the challenges in the development of anticancer drugs.

Citing Articles

A deadly taste: linking bitter taste receptors and apoptosis.

Miller Z, Carey R, Lee R Apoptosis. 2025; .

PMID: 39979526 DOI: 10.1007/s10495-025-02091-3.

Mechanistic exploration of bioactive constituents in Gnetum gnemon for GPCR-related cancer treatment through network pharmacology and molecular docking.

Chatatikun M, Pattaranggoon N, Sama-Ae I, Ranteh O, Poolpirom M, Pantanakong O Sci Rep. 2024; 14(1):25738.

PMID: 39468096 PMC: 11519448. DOI: 10.1038/s41598-024-75240-4.

GPCRs: emerging targets for novel T cell immune checkpoint therapy.

Dickinson K, Yee E, Vigil I, Schulick R, Zhu Y Cancer Immunol Immunother. 2024; 73(12):253.

PMID: 39358616 PMC: 11447192. DOI: 10.1007/s00262-024-03801-7.

Computational Characterization of Membrane Proteins as Anticancer Targets: Current Challenges and Opportunities.

Gorostiola Gonzalez M, Rakers P, Jespers W, IJzerman A, Heitman L, van Westen G Int J Mol Sci. 2024; 25(7).

PMID: 38612509 PMC: 11011372. DOI: 10.3390/ijms25073698.

Proton-sensing ion channels, GPCRs and calcium signaling regulated by them: implications for cancer.

Ji R, Chang L, An C, Zhang J Front Cell Dev Biol. 2024; 12:1326231.

PMID: 38505262 PMC: 10949864. DOI: 10.3389/fcell.2024.1326231.

References

Lundstrom K . Structural genomics of GPCRs. Trends Biotechnol. 2005; 23(2):103-8. DOI: 10.1016/j.tibtech.2004.12.006. View

Patrussi L, Capitani N, Martini V, Pizzi M, Trimarco V, Frezzato F . Enhanced Chemokine Receptor Recycling and Impaired S1P1 Expression Promote Leukemic Cell Infiltration of Lymph Nodes in Chronic Lymphocytic Leukemia. Cancer Res. 2015; 75(19):4153-63. DOI: 10.1158/0008-5472.CAN-15-0986. View

Fung S, Forte T, Rahal R, Niu J, Bryant H . Provincial rates and time trends in pancreatic cancer outcomes. Curr Oncol. 2013; 20(5):279-81. PMC: 3805404. DOI: 10.3747/co.20.1672. View

Young D, Waitches G, Birchmeier C, Fasano O, Wigler M . Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell. 1986; 45(5):711-9. DOI: 10.1016/0092-8674(86)90785-3. View

Duffy D, Box N, Chen W, Palmer J, Montgomery G, James M . Interactive effects of MC1R and OCA2 on melanoma risk phenotypes. Hum Mol Genet. 2004; 13(4):447-61. DOI: 10.1093/hmg/ddh043. View

Sic H, Kraus H, Madl J, Flittner K, von Munchow A, Pieper K . Sphingosine-1-phosphate receptors control B-cell migration through signaling components associated with primary immunodeficiencies, chronic lymphocytic leukemia, and multiple sclerosis. J Allergy Clin Immunol. 2014; 134(2):420-8. DOI: 10.1016/j.jaci.2014.01.037. View

Balkwill F . Cancer and the chemokine network. Nat Rev Cancer. 2004; 4(7):540-50. DOI: 10.1038/nrc1388. View

Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N . Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood. 2005; 106(5):1824-30. DOI: 10.1182/blood-2004-12-4918. View

Niedermeier M, Hennessy B, Knight Z, Henneberg M, Hu J, Kurtova A . Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood. 2009; 113(22):5549-57. PMC: 4580965. DOI: 10.1182/blood-2008-06-165068. View

10.

Feigin M, Xue B, Hammell M, Muthuswamy S . G-protein-coupled receptor GPR161 is overexpressed in breast cancer and is a promoter of cell proliferation and invasion. Proc Natl Acad Sci U S A. 2014; 111(11):4191-6. PMC: 3964064. DOI: 10.1073/pnas.1320239111. View

11.

Tuszynski G, Rothman V, Zheng X, Gutu M, Zhang X, Chang F . G-protein coupled receptor-associated sorting protein 1 (GASP-1), a potential biomarker in breast cancer. Exp Mol Pathol. 2011; 91(2):608-13. DOI: 10.1016/j.yexmp.2011.06.015. View

12.

Yang M, Zhong W, Srivastava N, Slavin A, Yang J, Hoey T . G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway. Proc Natl Acad Sci U S A. 2005; 102(17):6027-32. PMC: 1087935. DOI: 10.1073/pnas.0501535102. View

13.

Neuhaus E, Zhang W, Gelis L, Deng Y, Noldus J, Hatt H . Activation of an olfactory receptor inhibits proliferation of prostate cancer cells. J Biol Chem. 2009; 284(24):16218-16225. PMC: 2713531. DOI: 10.1074/jbc.M109.012096. View

14.

Xu J, Zhang C, He Y, Wu H, Wang Z, Song W . Lymphatic endothelial cell-secreted CXCL1 stimulates lymphangiogenesis and metastasis of gastric cancer. Int J Cancer. 2011; 130(4):787-97. DOI: 10.1002/ijc.26035. View

15.

Smith J, Fonkoua L, Moody T . The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies. Int J Biol Sci. 2016; 12(3):283-91. PMC: 4753157. DOI: 10.7150/ijbs.14952. View

16.

Matsuo Y, Raimondo M, Woodward T, Wallace M, Gill K, Tong Z . CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int J Cancer. 2009; 125(5):1027-37. DOI: 10.1002/ijc.24383. View

17.

. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388(10053):1545-1602. PMC: 5055577. DOI: 10.1016/S0140-6736(16)31678-6. View

18.

Bastiaens M, ter Huurne J, Kielich C, Gruis N, Westendorp R, Vermeer B . Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair. Am J Hum Genet. 2001; 68(4):884-94. PMC: 1275642. DOI: 10.1086/319500. View

19.

Chen J, Russo J . ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta. 2009; 1796(2):162-75. PMC: 2937358. DOI: 10.1016/j.bbcan.2009.06.003. View

20.

Labrie F, Belanger A, Luu-The V, Labrie C, Simard J, Cusan L . Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev. 2005; 26(3):361-79. DOI: 10.1210/er.2004-0017. View